文献速递淋巴瘤

利妥昔单抗时代滤泡性淋巴瘤患者每次复发后缓解持续时间和生存期缩短

Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era.
PubMed 文献 · Br J Haematol · 2018-12-04

本研究纳入两家机构2001至2014年新诊断并接受化学免疫治疗的348例滤泡性淋巴瘤患者,中位随访6.3年,10年无进展生存率和总生存率分别为53%和72%。一线、二线、三线治疗的5年缓解持续时间分别为62%、39%和24%(P<0.0001),提示利妥昔单抗时代每次复发后缓解持续时间仍缩短。

要点

  • 一线、二线、三线治疗的5年缓解持续时间分别为62%、39%和24%(P<0.0001)。
  • 一线治疗后缓解持续时间较长的患者,二线治疗后缓解持续时间也显著较长。
  • 二线治疗后自体干细胞移植对缓解持续时间无显著影响。

核心结论

  • 以利妥昔单抗联合方案一线治疗的滤泡性淋巴瘤患者,每次复发后缓解持续时间仍缩短。

研究设计与样本

  • 研究纳入两家机构2001至2014年新诊断并接受化学免疫治疗的348例滤泡性淋巴瘤患者。
  • 中位随访6.3年。

主要发现

  • 10年无进展生存率和总生存率分别为53%和72%。
  • 一线、二线、三线治疗的5年缓解持续时间分别为62%、39%和24%(P<0.0001)。
  • 预测一线治疗后缓解持续时间较长的变量为β2微球蛋白正常、达到完全缓解和利妥昔单抗维持治疗。
  • 一线治疗后缓解持续时间较长的患者,二线治疗后缓解持续时间显著较长。
  • 二线治疗后自体干细胞移植对缓解持续时间无显著影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma (FL) is an indolent disease characterized by long survival but frequent relapses. Before the introduction of rituximab, the clinical course of these patients showed a shorter response duration (RD) after each relapse. In this study, we analysed if this pattern of shortened responses remains in patients treated in the rituximab era. We selected 348 patients newly diagnosed with FL in two institutions between 2001 and 2014 that received chemoimmunotherapy. After a median follow-up of 6·3 years, 10-year progression-free and overall survivals were 53% and 72%, respectively. All patients received first-line, 111 second-line and 41 third-line treatments, with a 5-year RD of 62%, 39% and 24%, respectively (P < 0·0001). Variables predicting longer RD after first-line treatment were normal β2microglobulin, complete remission achievement and maintenance with rituximab. Patients with longer RD after first-line showed significantly longer RD after second-line therapy. Autologous stem-cell transplantation after second-line therapy did not significantly impact RD. Median survival after first, second and third therapies was not reached, 7·6 and 4·8 years, respectively, whereas relative survival with respect to a sex- and age-matched Spanish population, the decrease in the life expectancy at 10 years was 17%, 45% and 79%, respectively. Thus, RD still shortens after each relapse in patients with FL treated in first line with rituximab combinations.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rivas-Delgado A, Magnano L, Moreno-Velázquez M, et al. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol. 2018. PMID: 30515755. doi:10.1111/bjh.15708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。